Abarelix (PPI-149) is a gonadotropin releasing hormone (GnRH)/luteinizing hormone releasing hormone (LHRH) receptor (GnRHR, LHRHR) antagonist with low histamine release induction propensity (EC50 = 100 μg/mL; rat mast cells). Abarelix exhibits good in vivo efficacy via iv. or sc. in suppressing LH levels in castrated male rats (plasma LH = 12/1.2/0.9/1.2 ng/mL 6 hrs post 0/12.5/50/200 μg/kg in 5% mannitol sc.) and in lowering testosterone among intact male rats (plasma testosterone = 1.64/0.29 ng/mL 6 hrs post 0/3 μg/kg sc.).
British journal of clinical pharmacology, 70(4), 580-587 (2010-09-16)
Early studies on gonadotrophin-releasing hormone (GnRH) antagonists pointed out histamine-mediated anaphylactic reactions as a potential adverse effect of these drug candidates. In this study we have compared the histamine-releasing potential of four approved and marketed antagonists, degarelix, cetrorelix, abarelix and
Journal of medicinal chemistry, 44(3), 453-467 (2001-07-21)
A series of antagonists of gonadotropin-releasing hormone (GnRH) of the general formula Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph/4Amf(P)-D4Aph/D4Amf(Q)-Leu-ILys-Pro-DAla-NH2 was synthesized, characterized, and screened for duration of inhibition of luteinizing hormone release in a castrated male rat assay. Selected analogues were tested in a reporter gene
The Journal of pharmacology and experimental therapeutics, 301(1), 95-102 (2002-03-22)
We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists. At single subcutaneous injections of 0.3 to 10 microg/kg in rats, degarelix produced a dose-dependent suppression
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.